Form 4: Vivos Therapeutics Director Ralph Elias Green Acquires Stock Options

Director Ralph Elias Green received a grant of 4,000 stock options from Vivos Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Ralph Elias Green, a director of Vivos Therapeutics, Inc., received a grant of 4,000 stock options.
• The exercise price of these options is $2.38.
• One-half of the options vested immediately, one-fourth will vest on September 30, 2024, and the remaining one-fourth will vest on December 31, 2024.
• Following this transaction, Green beneficially owns 7,067 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The vesting schedule is a positive sign.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates